Plasma cell myeloma with RAS/BRAF mutations is frequently associated with a complex karyotype, advanced stage disease, and poorer prognosis
N Li, P Lin, Z Zuo, MJ You, W Shuai… - Cancer …, 2023 - Wiley Online Library
BACKGROUND Mutations in the RAS‐MAPK pathway, such as KRAS, NRAS, and BRAF,
are known as high‐risk factors associated with poor prognosis in patients with various …
are known as high‐risk factors associated with poor prognosis in patients with various …
New therapeutic options for hairy cell leukemia
A Janowska, A Janus, T Robak - Acta Haematologica …, 2022 - journals.viamedica.pl
Hairy cell leukemia (HCL) is a rare B-cell lymphoproliferative disorder characterized by
pancytopenia, splenomegaly and increased susceptibility to infections. In 2011, BRAF gene …
pancytopenia, splenomegaly and increased susceptibility to infections. In 2011, BRAF gene …
Plasma cell myeloma with RAS/BRAF mutations: Clinicopathologic, molecular genetic features and outcomes of 68 patients
N Li, P Lin, Z Zuo, MJ You, W Shuai, RZ Orlowski… - 2022 - researchsquare.com
High-throughput genomic analysis of plasma cell myeloma has identified recurrent gene
mutations of prognostic significance. Mutations in the RAS-MAPK pathway, such as KRAS …
mutations of prognostic significance. Mutations in the RAS-MAPK pathway, such as KRAS …
[PDF][PDF] Quelles sont les particularités du moxétumomab pasudotox dans le traitement de la tricholeucémie?
C Hamel, B Pharm - Pharmactuel, 2022 - core.ac.uk
Le pronostic des patients atteints de cette maladie s' est considérablement amélioré depuis
sa découverte dans les années 1950, principalement en raison d'une réponse de longue …
sa découverte dans les années 1950, principalement en raison d'une réponse de longue …